[177Lu]Lu-ART-101用于晚期前列腺癌放射配体治疗的临床前评估
本研究在PSMA表达的前列腺癌小鼠模型中评估了新型PSMA靶向放射配体[177Lu]Lu-ART-101的药代动力学、剂量学、疗效与毒性,并与[177Lu]Lu-PSMA-617比较。结果显示[177Lu]Lu-ART-101具有更高的肿瘤摄取和更长的滞留时间,肿瘤吸收剂量约为对照的2倍,在两种模型中均增强肿瘤控制并延长生存,安全性良好。
要点
- [177Lu]Lu-ART-101在PC3-PIP模型中肿瘤摄取峰值达14.3±1.5 %IA/g(48 h),滞留时间明显长于[177Lu]Lu-PSMA-617。
- 肿瘤吸收剂量为1.2±0.1([177Lu]Lu-ART-101)vs 0.6±0.1([177Lu]Lu-PSMA-617),约2倍。
- 正常组织分布不同:血循环时间更长、唾液腺摄取可忽略、主要经肝胆而非肾脏清除。
核心结论
- [177Lu]Lu-ART-101在晚期前列腺癌模型中显示出优于[177Lu]Lu-PSMA-617的疗效和良好安全性,支持其临床转化。
研究设计与样本
- 临床前研究:合成亲脂性ART-101并以177Lu标记,在PC3-PIP和LNCaP异种移植小鼠中评估疗效,在ICR正常小鼠中评估毒性。
主要发现
- 在PC3-PIP细胞中,[177Lu]Lu-ART-101的结合和内化模式与[177Lu]Lu-PSMA-617相似,且可被PSMA-617阻断,表明PSMA特异性结合。
- 体外竞争实验显示纳摩尔级结合亲和力,未标记ART-101竞争置换[177Lu]Lu-PSMA-617的半数抑制浓度为0.4±0.1 nM(PC3-PIP细胞)。
- PC3-PIP荷瘤裸鼠中,[177Lu]Lu-ART-101肿瘤摄取峰值14.3±1.5 %IA/g(注射后48 h),120和168 h分别滞留8.1±0.8和6.4±1.0 %IA/g;[177Lu]Lu-PSMA-617峰值10.0±2.0 %IA/g(2 h),120 h降至2.2±1.5 %IA/g。
- [177Lu]Lu-ART-101肿瘤吸收剂量1.2±0.1,[177Lu]Lu-PSMA-617为0.6±0.1,前者约高2倍。
- 在PC3-PIP和LNCaP模型中,[177Lu]Lu-ART-101均增强肿瘤控制并延长生存;ICR小鼠接受最高测试活度55.5 MBq时出现轻度一过性血细胞减少,第28天恢复,无肾、肝或组织学异常(包括骨髓和唾液腺)。
关键数值与推荐
- 体外竞争实验:未标记ART-101置换[177Lu]Lu-PSMA-617的半数抑制浓度为0.4±0.1 nM(PC3-PIP细胞)。
- PC3-PIP模型肿瘤吸收剂量:[177Lu]Lu-ART-101为1.2±0.1,[177Lu]Lu-PSMA-617为0.6±0.1。
- 毒性评估:ICR小鼠最高测试活度55.5 MBq时出现轻度一过性血细胞减少,第28天恢复,无其他器官异常。
临床怎么用
- 临床前数据提示[177Lu]Lu-ART-101可能较[177Lu]Lu-PSMA-617提高肿瘤吸收剂量并减少唾液腺和肾脏摄取,支持进一步临床转化研究。
局限性
- 研究为临床前小鼠模型,结果需在人体中验证。
- 毒性评估仅在正常ICR小鼠中进行,未在荷瘤模型中长期观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 has improved outcomes for patients with advanced prostate cancer (PCa), yet modest survival benefits underscore the need for more effective agents. Here, we describe the development of [177Lu]Lu-ART-101, a next-generation prostate-specific membrane antigen (PSMA)-targeting radioligand, and evaluate its biodistribution, dosimetry, therapeutic efficacy, and toxicity in advanced PSMA-expressing PCa models. Methods: Lipophilic ART-101 was synthesized and radiolabeled with 177Lu. [177Lu]Lu-ART-101 longitudinal biodistribution and dosimetry were assessed through SPECT/CT imaging in human PC3-PIP (PC3 cells engineered to overexpress PSMA) xenograft-bearing mice and compared with those of [177Lu]Lu-PSMA-617. The therapeutic efficacy of [177Lu]Lu-ART-101 was evaluated in the PC3-PIP and LNCaP xenograft-bearing mice, whereas toxicity was assessed in normal ICR mice. Results: [177Lu]Lu-ART-101 demonstrated patterns of cell binding and internalization similar to those of [177Lu]Lu-PSMA-617 in PC3-PIP cells. Internalization was effectively blocked by PSMA-617, indicating the PSMA-specific binding of [177Lu]Lu-ART-101. In vitro competition assays revealed potent nanomolar binding, with unlabeled ART-101 competitively displacing [177Lu]Lu-PSMA-617, with 0.4 ± 0.1 nM of inhibitory concentration of 50%, in PC3-PIP cells. In nude mice bearing PC3-PIP xenografts, [177Lu]Lu-ART-101 displayed higher tumor uptake (peak at 14.3 ± 1.5 %IA/g at 48 h after injection) and prolonged retention (8.1 ± 0.8 and 6.4 ± 1.0 %IA/g at 120 and 168 h, respectively) versus [177Lu]Lu-PSMA-617 (peak at 10.0 ± 2.0 %IA/g at 2 h) followed by a rapid decrease (2.2 ± 1.5 %IA/g at 120 h), leading to a 2-fold higher tumor absorbed dose with [177Lu]Lu-ART-101 (1.2 ± 0.1 vs. 0.6 ± 0.1). Notably, [177Lu]Lu-ART-101 showed a distinctive normal tissue distribution compared with [177Lu]Lu-PSMA-617, with longer blood circulation, negligible salivary gland uptake, and primarily hepatic rather than renal clearance. [177Lu]Lu-ART-101's favorable tumor dosimetry translated to enhanced tumor control and prolonged survival in both the PC3-PIP and LNCaP xenograft models. Safety studies in ICR mice revealed mild transient cytopenia in animals receiving the highest tested injected activity (55.5 MBq), which resolved by day 28, without concomitant renal, hepatic, or histologic abnormalities, including those in the bone marrow and salivary glands. Conclusion: [177Lu]Lu-ART-101 demonstrates significant potential as a novel radiopharmaceutical for advanced PCa, with superior therapeutic efficacy and a favorable safety profile. These findings support our ongoing clinical translation effort in advanced PCa.
引用
- Bio Idrissou M, Aguiar Ferreira C, Comas Rojas H, et al. Preclinical Evaluation of [177Lu]Lu-ART-101 for Radiopharmaceutical Therapy of Advanced Prostate Cancer. J Nucl Med. 2026. PMID: 41748297. doi:10.2967/jnumed.125.271543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。